Ieq Capital LLC Invests $1.22 Million in Iovance Biotherapeutics, Inc. $IOVA

Posted by on Aug 27th, 2026

Ieq Capital LLC bought a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 292,962 shares of the biotechnology company’s stock, valued at approximately $1,219,000. Ieq Capital LLC owned 0.06% of Iovance Biotherapeutics at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Royal Bank of Canada boosted its stake in shares of Iovance Biotherapeutics by 161.2% during the first quarter. Royal Bank of Canada now owns 522,887 shares of the biotechnology company’s stock valued at $1,740,000 after purchasing an additional 322,680 shares during the period. AQR Capital Management LLC increased its stake in shares of Iovance Biotherapeutics by 279.0% in the first quarter. AQR Capital Management LLC now owns 59,540 shares of the biotechnology company’s stock worth $195,000 after buying an additional 43,829 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Iovance Biotherapeutics by 30.5% in the first quarter. Goldman Sachs Group Inc. now owns 5,571,902 shares of the biotechnology company’s stock worth $18,554,000 after buying an additional 1,301,846 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Iovance Biotherapeutics by 202.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock worth $19,239,000 after buying an additional 3,869,617 shares during the period. Finally, Envestnet Asset Management Inc. raised its holdings in Iovance Biotherapeutics by 112.1% during the 2nd quarter. Envestnet Asset Management Inc. now owns 47,466 shares of the biotechnology company’s stock valued at $82,000 after buying an additional 25,083 shares during the last quarter. 77.03% of the stock is owned by hedge funds and other institutional investors.

Iovance Biotherapeutics Trading Down 4.3%

Shares of Iovance Biotherapeutics stock opened at $8.08 on Thursday. Iovance Biotherapeutics, Inc. has a 12-month low of $1.76 and a 12-month high of $9.36. The company has a market cap of $3.66 billion, a P/E ratio of -11.07 and a beta of 0.71. The company’s fifty day simple moving average is $5.30 and its two-hundred day simple moving average is $4.25.

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The firm had revenue of $198.63 million during the quarter, compared to analysts’ expectations of $87.83 million. During the same period last year, the company posted ($0.33) EPS. The company’s quarterly revenue was up 65.7% compared to the same quarter last year. Analysts predict that Iovance Biotherapeutics, Inc. will post -0.48 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on IOVA. Weiss Ratings reissued a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Thursday, July 2nd. TD Cowen upped their price objective on shares of Iovance Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Monday. Chardan Capital dropped their target price on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Barclays raised their target price on Iovance Biotherapeutics from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Citigroup restated an “outperform” rating on shares of Iovance Biotherapeutics in a report on Friday, August 7th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $8.89.

Get Our Latest Stock Analysis on Iovance Biotherapeutics

Iovance Biotherapeutics Profile

(Free Report)

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.

Featured Stories

Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.